MedTrace Logo

China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort)

NCT07309913 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 3459

Last updated 2025-12-30

No results posted yet for this study

Summary

The number of atrial fibrillation (AF) patients in China is approximately 32.76 million, with a prevalence rate of 2.3%. AF is associated with severe outcomes such as stroke and heart failure. Metabolic disorders (e.g., obesity, diabetes mellitus, dyslipidemia) are closely linked to the onset and prognosis of AF. However, the epidemiological characteristics and disease burden of AF combined with metabolic disorders in China remain unclear. Additionally, the impact of complex multi-dimensional metabolic disorders on AF prognosis requires further investigation, and current clinical guidelines lack targeted management recommendations for this population.

Conditions

Sponsors & Collaborators

  • Xiangya Hospital of Central South University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2036-02-01
Completion
2036-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07309913 on ClinicalTrials.gov